Cargando…
A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease
The aim of this study was to evaluate if amniotic fluid (AF) mixed with artificial tears or soaked with a soft contact lens (SCL) as a treatment for severe dry eye disease (DED) would improve its signs or symptoms. In this retrospective pilot study 22 consecutive eyes of 11 patients with level 3 DED...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medical Hypothesis, Discovery & Innovation Ophthalmology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592303/ https://www.ncbi.nlm.nih.gov/pubmed/31263717 |
_version_ | 1783429871251226624 |
---|---|
author | CHEN, Ming CHANG, Chao Kai LIN, Szu Yuan CHEN, Mindy |
author_facet | CHEN, Ming CHANG, Chao Kai LIN, Szu Yuan CHEN, Mindy |
author_sort | CHEN, Ming |
collection | PubMed |
description | The aim of this study was to evaluate if amniotic fluid (AF) mixed with artificial tears or soaked with a soft contact lens (SCL) as a treatment for severe dry eye disease (DED) would improve its signs or symptoms. In this retrospective pilot study 22 consecutive eyes of 11 patients with level 3 DED classified by DEWS 1 (Dry Eye WorkShop 1 2007), were included in the study between June 1 and September 30 in 2017. The study was conducted before DEWS II (Dry Eye WorkShop II 2017), which was published in October 2017. Therefore, DEWS II was not adopted for this study. Soft Contact Lens Acuvue Oasys of Plano with 8.8 base curve and 14 mm diameters by Johnson and Johnson were used to soak in FloGraft, which is an AF, for 30 minutes before placing in 12 eyes in Group 1. The contact lenses were placed in the left eye for 1 week. In Group 2, 10 eyes used 6 mL of artificial tears mixed with 0.25 mL of AF, which were applied to the eye four times a day for 1 week. No other eye medications were used. The eyes that were included had diffuse punctate staining and fast tear breaking times of <5 seconds with severe ocular symptoms (DEWS 1 level 3-4). Photos of fluorescein stain corneas before the treatment and 1 week after the treatment were used to compare the distribution of punctate staining as the objective outcomes for signs. Several questions adopted from the Ocular Surface disease Index (OSDI) about subjective symptoms before and after the treatment were asked, and documented on the chart. Improvement either in symptoms or signs or both of DED after 1 week at follow-up examination was recorded. Group 1, with SCL 46% had improvement after 1 week and Group 2, with artificial tears 50% had improvement after 1 week. Improvement means either symptom relief or comparatively decreased distribution of punctate staining on the cornea or both. No cases had inflammation, infection, irritation or blurred vision. We concluded that FloGraft as an AF can safely improve the symptoms or the signs of severe DED either as a mix with artificial tears or soaked with SCL by about 50% in this case series without evidence of irritation, inflammation or blurred vision in the short term. |
format | Online Article Text |
id | pubmed-6592303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Medical Hypothesis, Discovery & Innovation Ophthalmology |
record_format | MEDLINE/PubMed |
spelling | pubmed-65923032019-07-01 A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease CHEN, Ming CHANG, Chao Kai LIN, Szu Yuan CHEN, Mindy Med Hypothesis Discov Innov Ophthalmol Original Article The aim of this study was to evaluate if amniotic fluid (AF) mixed with artificial tears or soaked with a soft contact lens (SCL) as a treatment for severe dry eye disease (DED) would improve its signs or symptoms. In this retrospective pilot study 22 consecutive eyes of 11 patients with level 3 DED classified by DEWS 1 (Dry Eye WorkShop 1 2007), were included in the study between June 1 and September 30 in 2017. The study was conducted before DEWS II (Dry Eye WorkShop II 2017), which was published in October 2017. Therefore, DEWS II was not adopted for this study. Soft Contact Lens Acuvue Oasys of Plano with 8.8 base curve and 14 mm diameters by Johnson and Johnson were used to soak in FloGraft, which is an AF, for 30 minutes before placing in 12 eyes in Group 1. The contact lenses were placed in the left eye for 1 week. In Group 2, 10 eyes used 6 mL of artificial tears mixed with 0.25 mL of AF, which were applied to the eye four times a day for 1 week. No other eye medications were used. The eyes that were included had diffuse punctate staining and fast tear breaking times of <5 seconds with severe ocular symptoms (DEWS 1 level 3-4). Photos of fluorescein stain corneas before the treatment and 1 week after the treatment were used to compare the distribution of punctate staining as the objective outcomes for signs. Several questions adopted from the Ocular Surface disease Index (OSDI) about subjective symptoms before and after the treatment were asked, and documented on the chart. Improvement either in symptoms or signs or both of DED after 1 week at follow-up examination was recorded. Group 1, with SCL 46% had improvement after 1 week and Group 2, with artificial tears 50% had improvement after 1 week. Improvement means either symptom relief or comparatively decreased distribution of punctate staining on the cornea or both. No cases had inflammation, infection, irritation or blurred vision. We concluded that FloGraft as an AF can safely improve the symptoms or the signs of severe DED either as a mix with artificial tears or soaked with SCL by about 50% in this case series without evidence of irritation, inflammation or blurred vision in the short term. Medical Hypothesis, Discovery & Innovation Ophthalmology 2019 /pmc/articles/PMC6592303/ /pubmed/31263717 Text en © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (http://creativecommons.org/licenses/by/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited. |
spellingShingle | Original Article CHEN, Ming CHANG, Chao Kai LIN, Szu Yuan CHEN, Mindy A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease |
title | A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease |
title_full | A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease |
title_fullStr | A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease |
title_full_unstemmed | A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease |
title_short | A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease |
title_sort | pilot study of the short term effectiveness and safety of amniotic fluid in severe dry eye disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592303/ https://www.ncbi.nlm.nih.gov/pubmed/31263717 |
work_keys_str_mv | AT chenming apilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease AT changchaokai apilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease AT linszuyuan apilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease AT chenmindy apilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease AT chenming pilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease AT changchaokai pilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease AT linszuyuan pilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease AT chenmindy pilotstudyoftheshorttermeffectivenessandsafetyofamnioticfluidinseveredryeyedisease |